Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Massachusetts General Hospital
University of California, Irvine
City of Hope Medical Center
Jonsson Comprehensive Cancer Center
Children's Oncology Group
Dana-Farber Cancer Institute
Albert Einstein College of Medicine
Fred Hutchinson Cancer Center
Barbara Ann Karmanos Cancer Institute
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
University of Maryland, Baltimore
University of Maryland, Baltimore
Children's Oncology Group
Sarcoma Alliance for Research through Collaboration
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
Dana-Farber Cancer Institute
GOG Foundation
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
NYU Langone Health
City of Hope Medical Center
NYU Langone Health
National Cancer Institute (NCI)
Indiana University
Children's Oncology Group
Children's Oncology Group